FTC 联合七个州要求法院认定 Martin Shkreli 藐视法庭
STAT+: FTC demands Martin Shkreli divest his pharma stocks
美国联邦贸易委员会(FTC)与七个州于周二向联邦法院申请,要求认定 Martin Shkreli 因“公然且反复”违反禁止其进入制药行业的法庭命令而构成藐视法庭。该禁令源于 2018 年其因欺诈投资者被判刑期间,法院认定其非法阻止 daraprim 药品面临仿制药竞争而下的行业禁入令。
Federal agency and 7 states accuse ‘pharma bro’ of ‘flagrantly’ violating a court order
![]()
By Jason Mast
Oct. 13, 2026
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
Martin Shkreli is back. The Federal Trade Commission isn’t happy.
The FTC and seven states on Tuesday asked a federal court to hold Shkreli in contempt for “flagrantly and repeatedly” violating a court order banning him from working in the pharmaceutical industry.
Shkreli, who became known nationwide as “pharma bro” in the 2010s for imperiously defending his decision to raise the price of an anti-parasitic drug called daraprim by 5,000%, was sentenced to seven years in prison for defrauding investors in 2018. Before he was released in 2022, a court banned him from ever working in the drug industry again, saying he illegally tried to prevent generic competition to daraprim.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
来源:STAT 主站 · statnews.com